Clinical trials · Los Angeles, CA
Small Cell Lung Cancer clinical trials in Los Angeles
We’re tracking 222 recruiting small cell lung cancer studies with a site in or near Los Angeles — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Los Angeles
- NCT06890598RecruitingPhase 3
Study of olomorasib for KRAS G12C-mutant lung cancer
This trial tests a new targeted therapy (olomorasib) combined with standard treatments for people with a specific type of non-small cell lung cancer that has a KRAS G12C mutation. Depending on the stage of your cancer, you may receive it before or after surgery, or along with chemotherapy and radiation.
Los Angeles, CaliforniaAges 18 years+ - NCT05361174RecruitingPhase 1/Phase 2
Testing an IOV-4001 infusion for advanced melanoma or lung cancer
This trial studies how well and how safely an infusion called IOV-4001 works in adults with advanced melanoma or non-small-cell lung cancer that cannot be removed with surgery. It also aims to see what side effects occur and whether the treatment can help control the cancer.
Los Angeles, CaliforniaAges 18–70 - NCT06362252RecruitingPhase 1/Phase 2
I-DXd plus atezolizumab for first-line extensive SCLC
This trial tests a new combination of drugs (I-DXd and atezolizumab, with or without carboplatin) as your first treatment for extensive stage small cell lung cancer. It has two groups: one for people who haven't started treatment yet, and another for those who've already had 4 cycles of a standard chemo-immunotherapy combination and are stable or better.
Los Angeles, CaliforniaAges 18 years+ - NCT07459634RecruitingPhase 2
Lurbinectedin with durvalumab for extensive-stage small cell lung cancer
This trial tests a new combination of two drugs, lurbinectedin and durvalumab, for people with extensive-stage small cell lung cancer (ES-SCLC) who have already received four cycles of standard platinum-based chemotherapy along with durvalumab. The goal is to see if this combination can help control the cancer further.
Los Angeles, CaliforniaAges 18 years+ - NCT05642572RecruitingPhase 2
Test drug combinations for EGFR- and MET-changed lung cancer
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
Los Angeles, CaliforniaAges 18 years+ - NCT04928846RecruitingPhase 3
Telisotuzumab vedotin vs docetaxel for advanced non-squamous lung cancer
This trial tests an investigational drug (telisotuzumab vedotin) against the standard chemotherapy docetaxel in people with a certain type of non-squamous lung cancer that has high levels of a protein called c-Met. It may offer a new treatment option for those whose cancer has progressed after initial therapy.
Los Angeles, CaliforniaAges 18 years+ - NCT05588388RecruitingPhase 2
Testing bevacizumab with chemo and immunotherapy for small cell lung cancer
This Phase 2 trial studies whether adding bevacizumab to chemo plus immunotherapy (including atezolizumab) can improve outcomes in extensive-stage small cell lung cancer (ES-SCLC) that has spread to the liver. It may help by blocking tumor blood vessel growth while boosting anti-cancer immune and treatment effects.
Los Angeles, CaliforniaAges Any age - NCT05401110RecruitingPhase 1
Osimertinib plus antibody treatment for EGFR-mutated lung cancer
This Phase 1 study tests the combination of osimertinib (a targeted lung cancer pill) with an antibody called carotuximab to treat advanced EGFR-mutated non-small cell lung cancer. It aims to see whether adding the antibody can help when the cancer has grown despite prior EGFR-targeted therapy.
Los Angeles, CaliforniaAges 18 years+ - NCT07458347RecruitingPhase 1
A new oral drug for KRAS-mutated advanced cancer
This trial tests a new oral drug, KST-6051, for people with advanced solid tumors (like lung, pancreatic, colon, or other cancers) that have a specific KRAS gene mutation. The goal is to find the best dose and see if it's safe.
Los Angeles, CaliforniaAges 18 years+ - NCT06476808RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an investigational drug (BMS-986463) in people with advanced solid tumors. It aims to find a safe dose and see if it helps shrink or control the cancer. You must be well enough to do daily activities and have a tumor that can be biopsied before treatment starts.
Los Angeles, CaliforniaAges 18 years+ - NCT06031688RecruitingPhase 2
Targeted treatment for lung cancer with a MET gene change
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
Los Angeles, CaliforniaAges 18 minutes+ - NCT06472245RecruitingPhase 3
Cancer vaccine for lung cancer that stopped responding to immunotherapy
This trial tests a therapeutic cancer vaccine called OSE2101 for people with advanced non-small cell lung cancer whose tumors stopped responding to an immunotherapy drug. The vaccine is designed to help your immune system fight the cancer in a different way.
Los Angeles, CaliforniaAges 18 years+ - NCT07186699Recruiting
Understanding lung cancer in people with past alcohol or drug use
This study looks at the experiences of people with lung cancer (NSCLC) who also have a history of alcohol or drug use. It aims to help doctors better understand and support patients facing both challenges.
Los Angeles, CaliforniaAges 18 years+ - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Los Angeles, CaliforniaAges 18 years+ - NCT07127874RecruitingPhase 1
Study of PHN-012 for advanced solid tumors
This trial tests a new drug called PHN-012 for people with advanced colorectal, non-small cell lung, or pancreatic cancer who have already tried at least one standard treatment. The goal is to see if the drug can help shrink or slow tumor growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06767514RecruitingPhase 3
Ivonescimab for first-line treatment of advanced NSCLC with high PD-L1
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06623422RecruitingPhase 3
Vaccine plus Keytruda for lung cancer after surgery
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
Los Angeles, CaliforniaAges 18 years+ - NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for KRAS G12D solid tumors
This trial tests a new oral drug called VS-7375 for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06060613RecruitingPhase 1/Phase 2
OBX-115 cell therapy for advanced melanoma or lung cancer
This trial tests an experimental cell therapy called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments. The therapy uses your own immune cells to fight the cancer. The study aims to see if it is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT05098132RecruitingPhase 1/Phase 2
STK-012 drug for advanced lung cancer and other tumors
This trial tests STK-012 (alone and with other treatments) in people with advanced cancers, especially non-small cell lung cancer. It may help by activating the immune system to recognize and fight the tumor.
Los Angeles, CaliforniaAges 18 years+ - NCT07566052RecruitingPhase 3
Comparing a new KRAS drug to docetaxel for advanced lung cancer
This trial tests a new pill (setidegrasib) against a standard chemo drug (docetaxel) for people with a specific type of advanced lung cancer that has a KRAS G12D mutation. The goal is to see which treatment works better.
Glendale, CaliforniaAges 18 years+ - NCT07195695RecruitingPhase 3
Zongertinib after surgery for HER2-mutated lung cancer
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
Glendale, CaliforniaAges 18 years+ - NCT05168566RecruitingPhase 2
Sutetinib for lung cancer with a specific EGFR change
This Phase 2 study tests sutetinib capsules in people with advanced (locally advanced or metastatic) non-small cell lung cancer. It’s for tumors that have a specific, uncommon EGFR mutation, and aims to see how well the drug can control the cancer with limited prior chemotherapy.
Glendale, CaliforniaAges 18 years+ - NCT06745908RecruitingPhase 3
New drug combo for lung cancer after immunotherapy stops working
This trial tests a new drug combination (N-803 and tislelizumab with chemotherapy) for people whose lung cancer stopped responding to standard immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Glendale, CaliforniaAges 18–90
Hear when a new Small Cell Lung Cancer trial opens near Los Angeles, CA
We’ll email you when one opens near Los Angeles, CA — at most once a week, no account needed, unsubscribe anytime.
Small Cell Lung Cancer trials in other cities
Where these studies are running near Los Angeles
Institutions with a site for the recruiting small cell lung cancer studies listed above.
- Cedars-Sinai Medical Center · 7 studies
- OPN Healthcare, Inc. · 3 studies
- University of Southern California · 3 studies
- Hoag Memorial Hospital Presbyterian · 2 studies
- Kaiser Permanente Anaheim Kraemer Medical Offices · 2 studies
- Kaiser Permanente Baldwin Park Medical Center · 2 studies
- Kaiser Permanente Bellflower Medical Offices · 2 studies
- Kaiser Permanente Fontana Medical Center · 2 studies
What taking part in a small cell lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting small cell lung cancer studies in California.
Common questions
- Are there small cell lung cancer clinical trials near Los Angeles?
- Yes. We're currently tracking 222 recruiting small cell lung cancer studies with a site near Los Angeles, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a small cell lung cancer study near Los Angeles?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Los Angeles to take part?
- Not necessarily. These studies have a site near Los Angeles, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New small cell lung cancer studies open near Los Angeles regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.